Forte Biosciences Inc (OQ:FBRX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3060 PEGASUS PARK DRIVE, BUILDING 6
DALLAS TX 75247
Tel: N/A
Website: https://www.fortebiorx.com/home/default.aspx
IR: See website
<
Key People
Paul A. Wagner
Chairman of the Board, Chief Executive Officer
Hubert C. Chen
President, Chief Scientific Officer
Antony A. Riley
Chief Financial Officer
Business Overview
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company's FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company's subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Financial Overview
For the fiscal year ended 31 December 2023, Forte Biosciences Inc revenues was not reported. Net loss increased from $13.9M to $31.5M. Higher net loss reflects Research and development - Balancing val increase from $4.3M to $20.7M (expense), General and administrative - Balancing increase of 54% to $8.5M (expense), Other income (expenses) decrease from $17K (income) to $114K (expense).
Employees: 9 as of Mar 11, 2024
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$32.48M as of Dec 31, 2023
Net annual income (TTM): -$31.48M as of Dec 31, 2023
Free cash flow (TTM): -$28.72M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 36,394,882 as of Mar 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.